Vertex Pharmaceuticals (VRTX) Other Gross PP&E Adjustments (2009 - 2026)

Vertex Pharmaceuticals has reported Other Gross PP&E Adjustments for 18 years, with the latest figure at -$1.7 billion in Q1 2026.

• For the quarter ending Q1 2026, Other Gross PP&E Adjustments fell 25.89% year-over-year to -$1.7 billion; the trailing twelve-month figure through Mar 2026 stood at -$1.7 billion (down 25.89% YoY), and the FY2025 full-year result was $989.9 million, up 28.29% from the prior year.
• Other Gross PP&E Adjustments for Q1 2026 stood at -$1.7 billion, down from $989.9 million in the prior quarter.
• The five-year high for Other Gross PP&E Adjustments was $1.9 billion in Q4 2023, with the low at -$1.7 billion in Q1 2026.
• Average Other Gross PP&E Adjustments over 5 years is -$282.4 million, with a median of -$329.0 million recorded in 2022.
• Year-over-year, Other Gross PP&E Adjustments slumped 349.63% in 2024 and advanced 28.29% in 2025.
• Tracing VRTX's Other Gross PP&E Adjustments over 5 years: stood at $1.7 billion in 2022, then rose by 12.66% to $1.9 billion in 2023, then tumbled by 59.61% to $771.6 million in 2024, then grew by 28.29% to $989.9 million in 2025, then sank by 270.23% to -$1.7 billion in 2026.
• The last three Other Gross PP&E Adjustments figures came in at -$1.7 billion (Q1 2026), $989.9 million (Q4 2025), and -$1.6 billion (Q3 2025), per Business Quant data.

Peer Comparison